Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Preferred Stock Liabilities (2019)

4D Molecular Therapeutics (FDMT) has disclosed Preferred Stock Liabilities for 1 consecutive years, with $103.0 million as the latest value for Q4 2019.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $103.0 million in Q4 2019 year-over-year; TTM through Dec 2019 was $103.0 million, a N/A change, with the full-year FY2019 number at $103.0 million, changed N/A from a year prior.
  • Preferred Stock Liabilities was $103.0 million for Q4 2019 at 4D Molecular Therapeutics.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $103.0 million in Q4 2019 to a low of $103.0 million in Q4 2019.